A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

被引：0
|
作者：
Phiri, Kelesitse [1 ]
Hallas, Jesper [2 ]
Linder, Marie [3 ]
Margulis, Andrea [4 ]
Suehs, Brandon [5 ]
Arana, Alejandro [4 ]
Bahmanyar, Shahram [3 ]
Enger, Cheryl [1 ]
Horter, Libby [5 ]
Odsbu, Ingvild [3 ]
Olesen, Morten [2 ]
Perez-Gutthann, Susana [4 ]
Kristiansen, Nina Sahlertz [2 ]
Appenteng, Kwame [6 ]
de Vogel, Stefan [7 ]
Seeger, John [1 ]
机构：
[1] Optum, Boston, MA USA
[2] Univ Southern Denmark, Odense, Denmark
[3] Karolinska Inst, Stockholm, Sweden
[4] RTI Hlth Solut, Barcelona, Spain
[5] Humana Healthcare Res, Louisville, KY USA
[6] Astellas Pharma US, Northbrook, IL USA
[7] Astellas Pharma BV, Leiden, Netherlands
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4352
引用
收藏
页码：465 / 465
页数：1
相关论文
共 50 条
  • [21] A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study)
    Ko, Kwang Jin
    Choo, Myung-Soo
    Chang, Young-Seop
    Kim, Joon Chul
    Lee, Kyu-Sung
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 (08) : 2417 - 2424
  • [22] Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study
    Hallas, Jesper
    Margulis, Andrea V.
    Pottegard, Anton
    Kristiansen, Nina S.
    Atsma, Willem J.
    Appenteng, Kwame
    de Vogel, Stefan
    Kaye, James A.
    Perez-Gutthann, Susana
    Arana, Alejandro
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (06) : 612 - 619
  • [23] Mirabegron (Myrbetriq) for Overactive Bladder
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1410): : 13 - 15
  • [24] OBJECTIVE EFFICACY OF MIRABEGRON ON STORAGE AND VOIDING FUNCTION IN PATIENTS WITH OVERACTIVE BLADDER THAT IS UNRESPONSIVE TO ANTIMUSCARINIC TREATMENT, BASED ON A URODYNAMIC STUDY
    Matsukawa, Yoshihisa
    Takai, Shun
    Tsuruta, Katsuhisa
    Kato, Masashi
    Yamamoto, Tokunori
    Gotoh, Momokazu
    JOURNAL OF UROLOGY, 2014, 191 (04): : E873 - E873
  • [25] Cardiovascular Risk in Users of Antimuscarinic Drugs for Overactive Bladder: A Cohort Study in the Swedish National Registers
    Linder, Marie
    Margulis, Andrea V.
    Anveden-Berglind, Ingegard
    Bahmanyar, Shahram
    Bui, Christine L.
    Atsma, Willem Jan
    Appenteng, Kwame
    Franks, Billy
    de Vogel, Stefan
    D'Silva, Milbhor
    Perez-Gutthann, Susana
    Arana, Alejandro
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 493 - 493
  • [26] OBJECTIVE EFFICACY OF MIRABEGRON ON STORAGE AND VOIDING FUNCTION IN PATIENTS WITH OVERACTIVE BLADDER THAT IS UNRESPONSIVE TO ANTIMUSCARINIC TREATMENT, BASED ON A URODYNAMIC STUDY
    Matsukawa, Y.
    Takai, S.
    Matsuo, K.
    Funahashi, Y.
    Yoshino, Y.
    Yamamoto, T.
    Gotoh, M.
    NEUROUROLOGY AND URODYNAMICS, 2015, 34 : S400 - S400
  • [27] Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice
    Chapple, Christopher R.
    Nazir, Jameel
    Hakimi, Zalmai
    Bowditch, Sally
    Fatoye, Francis
    Guelfucci, Florent
    Khemiri, Amine
    Siddiqui, Emad
    Wagg, Adrian
    EUROPEAN UROLOGY, 2017, 72 (03) : 389 - 399
  • [28] Analysis of costs and consequences related to the persistence of Mirabegron and antimuscarinic treatments and their impact on quality of life in patients with overactive bladder in Spain: Results of a probabilistic model
    Arlandis Guzman, Salvador
    Jimenez Cidre, Niguel Angel
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    Landeira, Margarita
    Blanco, Nuria
    ARCHIVOS ESPANOLES DE UROLOGIA, 2020, 73 (06): : 509 - 522
  • [29] ANALYSIS OF COST AND CONSEQUENCES RELATED TO THE PERSISTENCE OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS AND THEIR IMPACT ON QUALITY OF LIFE IN PATIENTS AGED ≥ 65 YEARS WITH OVERACTIVE BLADDER IN SPAIN
    Arlandis Guzman, S.
    Jimenez-Cidre, M.
    Rubio-Rodriguez, D.
    Rubio Terres, C.
    Landeira, M.
    Blanco, N.
    VALUE IN HEALTH, 2019, 22 : S915 - S915
  • [30] Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults Overactive Bladder in the United Kingdom
    Nazir, Jameel
    Maman, Khaled
    Neine, Mohamed-Elmoctar
    Briquet, Benjamin
    Odeyemi, Isaac A. O.
    Hakimi, Zalmai
    Garnham, Andy
    Aballea, Samuel
    VALUE IN HEALTH, 2015, 18 (06) : 783 - 790
12345